BDP1改变与乳腺癌的临床结局相关。

BDP1 Alterations Correlate with Clinical Outcomes in Breast Cancer.

作者信息

Cabarcas-Petroski Stephanie, Schramm Laura

机构信息

Department of Biology, Beaver Campus, Pennsylvania State University, Monaca, PA 15061, USA.

Department of Biology, St. John's University, Queens, NY 11439, USA.

出版信息

Cancers (Basel). 2022 Mar 25;14(7):1658. doi: 10.3390/cancers14071658.

DOI:10.3390/cancers14071658

PMID:35406430

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8996959/

Abstract

TFIIIB is deregulated in a variety of cancers. However, few studies investigate the TFIIIB subunit BDP1 in cancer. BDP1 has not been studied in breast cancer patients. Herein, we analyzed clinical breast cancer datasets to determine if BDP1 alterations correlate with clinical outcomes. BDP1 copy number ( 1602; 8.03 × 10) and mRNA expression ( 130; 0.002) are specifically decreased in patients with invasive ductal carcinoma (IDC). In IDC, BDP1 copy number negatively correlates with high grade ( 1992; 2.62 × 10) and advanced stage ( 1992; 0.005). BDP1 mRNA expression also negatively correlated with high grade ( 55; 6.81 × 10) and advanced stage ( 593; 4.66 × 10) IDC. Decreased BDP1 expression correlated with poor clinical outcomes ( 295 samples): a metastatic event at three years ( 7.79 × 10) and cancer reoccurrence at three years ( 4.81 × 10) in IDC. Decreased BDP1 mRNA correlates with patient death at three ( 9.90 × 10) and five ( 1.02 × 10) years. Both BDP1 copy number ( 3785; 1.0 × 10) and mRNA expression ( 2434; 5.23 × 10) are altered in triple-negative invasive breast cancer (TNBC). Together, these data suggest a role for BDP1 as potential biomarker in breast cancer and additional studies are warranted.

摘要

TFIIIB在多种癌症中失调。然而，很少有研究在癌症中调查TFIIIB亚基BDP1。尚未在乳腺癌患者中研究BDP1。在此，我们分析了临床乳腺癌数据集，以确定BDP1改变是否与临床结果相关。浸润性导管癌（IDC）患者的BDP1拷贝数（1602；8.03×10）和mRNA表达（130；0.002）特异性降低。在IDC中，BDP1拷贝数与高级别（1992；2.62×10）和晚期（1992；0.005）呈负相关。BDP1 mRNA表达也与高级别（55；6.81×10）和晚期（593；4.66×10）的IDC呈负相关。BDP1表达降低与不良临床结果相关（295个样本）：IDC患者三年时的转移事件（7.79×10）和三年时的癌症复发（4.81×10）。BDP1 mRNA降低与患者三年（9.90×10）和五年（1.02×10）时的死亡相关。三阴性浸润性乳腺癌（TNBC）中BDP1拷贝数（3785；1.0×10）和mRNA表达（2434；5.23×10）均发生改变。总之，这些数据表明BDP1作为乳腺癌潜在生物标志物的作用，有必要进行更多研究。